A survival score for patients receiving stereotactic radiosurgery alone for brain metastases from breast cancer

Dirk Rades, Liesa Dziggel, Stefan Janssen, Oliver Blanck, Dagmar Hornung, Steven E. Schild

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Aim: To generate a survival score for patients with breast cancer treated with stereotactic radiosurgery (SRS) alone for brain metastases. Patients and Methods: Seven factors were evaluated in 34 patients, namely age, performance score, number of brain metastases, maximum diameter of all brain metastases, location of brain metastases, extracerebral metastases and time between breast cancer diagnosis and SRS. The score was created from factors having a significant impact on survival. Points of 0 (worse survival) or 1 (better survival) were assigned. Factor scores were added to total prognostic scores for each patient. Results: A significant impact on survival was found for performance score (p<0.001), maximum diameter of cerebral lesions (p=0.002), and extracerebral metastases (p=0.026). Three groups were designated by score: 0-1, 2 and 3 points. One-year survival rates were 48%, 71% and 100%, respectively (p<0.001). Conclusion: This score contributes to appropriate selection of personalized treatment in patients with breast cancer with few cerebral metastases.

Original languageEnglish (US)
Pages (from-to)1073-1076
Number of pages4
JournalAnticancer Research
Volume36
Issue number3
StatePublished - Mar 1 2016

Keywords

  • Breast cancer
  • Limited number of brain metastases
  • Prognostic score
  • Stereotactic radiosurgery
  • Survival analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A survival score for patients receiving stereotactic radiosurgery alone for brain metastases from breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Rades, D., Dziggel, L., Janssen, S., Blanck, O., Hornung, D., & Schild, S. E. (2016). A survival score for patients receiving stereotactic radiosurgery alone for brain metastases from breast cancer. Anticancer Research, 36(3), 1073-1076.